ImmuCell Corporation (ICCC)

ImmuCell Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	21.28	17.47	18.57	19.24	15.34	13.72
Revenue Growth (YoY)	32.89%	-5.90%	-3.51%	25.43%	11.80%	24.91%
Cost of Revenue	15.42	13.6	10.92	10.59	8.48	6.98
Gross Profit	5.86	3.87	7.65	8.66	6.86	6.74
Selling, General & Admin	5.11	5.22	5.45	4.23	3.89	4.01
Research & Development	4.55	4.39	4.49	4.17	4.35	3.69
Operating Expenses	9.66	9.62	9.95	8.4	8.24	7.69
Operating Income	-3.79	-5.75	-2.3	0.26	-1.38	-0.95
Other Expense / Income	0.1	0.02	0.19	0.33	-0.35	0.31
Pretax Income	-3.89	-5.77	-2.49	-0.07	-1.03	-1.27
Income Tax	0	0	0.01	0.01	-0.01	0.03
Net Income	-3.9	-5.77	-2.49	-0.08	-1.02	-1.3
Shares Outstanding (Basic)	8	8	8	8	7	7
Shares Outstanding (Diluted)	8	8	8	8	7	7
Shares Change	0.05%	0.03%	2.01%	5.25%	5.78%	24.29%
EPS (Basic)	-0.51	-0.75	-0.32	-0.01	-0.14	-0.19
EPS (Diluted)	-0.51	-0.75	-0.32	-0.01	-0.14	-0.19
Free Cash Flow	-2.77	-6.56	-5.51	-1.64	-2.71	-0.71
Free Cash Flow Per Share	-0.36	-0.85	-0.71	-0.22	-0.38	-0.10
Gross Margin	27.55%	22.15%	41.19%	44.98%	44.73%	49.11%
Operating Margin	-17.82%	-32.90%	-12.38%	1.34%	-9.00%	-6.95%
Profit Margin	-18.31%	-33.05%	-13.43%	-0.41%	-6.66%	-9.44%
Free Cash Flow Margin	-13.02%	-37.57%	-29.66%	-8.52%	-17.67%	-5.16%
EBITDA	-1.17	-3.05	0	2.39	1.32	1
EBITDA Margin	-5.48%	-17.47%	0.01%	12.43%	8.57%	7.29%
Depreciation & Amortization	2.73	2.72	2.49	2.46	2.35	2.27
EBIT	-3.89	-5.77	-2.49	-0.07	-1.03	-1.27
EBIT Margin	-18.29%	-33.02%	-13.39%	-0.36%	-6.73%	-9.24%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).